BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 35902718)

  • 1. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.
    Jácome AA; Wohnrath DR; Scapulatempo Neto C; Carneseca EC; Serrano SV; Viana LS; Nunes JS; Martinez EZ; Santos JS
    Gastric Cancer; 2014 Jan; 17(1):76-86. PubMed ID: 23455716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer.
    D'Angelo F; Monnien F; Overs A; Pem I; Dor F; Abad M; Felix S; Selmani Z; Lakkis Z; Borg C; Doussot A; Bibeau F; Molimard C
    Diagn Pathol; 2024 Jun; 19(1):88. PubMed ID: 38909265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 status is positively associated with vessel invasion of colorectal cancer: a retrospective large cohort study.
    Wang M; Wang X; Li Y; Li Q; Cai S; Li X; Ma M
    Int J Colorectal Dis; 2022 Sep; 37(9):2061-2067. PubMed ID: 36006442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room.
    Raghav KPS; Loree JM; Kopetz S
    Clin Cancer Res; 2024 Jan; 30(2):260-262. PubMed ID: 37975903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of colorectal carcinoid tumors.
    Colonoscopy Study Group of Korean Society of Coloproctology
    J Korean Soc Coloproctol; 2011 Feb; 27(1):17-20. PubMed ID: 21431092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX9 immunosuppression in primary colorectal cancer tumors with lymph node metastasis.
    Gutiérrez-Gil MC; Espino-Larralde M; Loza-González VM; Hernández-Rodríguez HG
    Rev Gastroenterol Mex (Engl Ed); 2024 Jun; ():. PubMed ID: 38862362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Hepcidin and Neogenin in Colorectal Cancer.
    Xiang-Tao P
    Open Med (Wars); 2017; 12():184-188. PubMed ID: 28730177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iterative local Gaussian clustering for expressed genes identification linked to malignancy of human colorectal carcinoma.
    Wasito I; Hashim SZ; Sukmaningrum S
    Bioinformation; 2007 Dec; 2(5):175-81. PubMed ID: 18305825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction to: TAS2940, A novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
    Cancer Sci; 2024 May; 115(5):1718. PubMed ID: 38270288
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
    Kwon HJ; Park Y; Nam SK; Kang E; Kim KK; Jeong I; Kwak Y; Yoon J; Kim TY; Lee KW; Oh DY; Im SA; Kong SH; Park DJ; Lee HJ; Kim HH; Yang HK; Lee HS
    Cancer Med; 2023 May; 12(9):10371-10384. PubMed ID: 36916290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-Positive Metastatic Colorectal Cancer.
    Robinson HR; Messersmith WA; Lentz RW
    Curr Treat Options Oncol; 2024 May; 25(5):585-604. PubMed ID: 38539034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?
    Halder S; Basu S; Lall SP; Ganti AK; Batra SK; Seshacharyulu P
    Expert Opin Ther Targets; 2023; 27(4-5):305-324. PubMed ID: 37243489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives.
    Elkamhawy A; Son S; Lee HY; El-Maghrabey MH; Hamd MAE; Alshammari SO; Abdelhameed AA; Alshammari QA; Abdeen A; Ibrahim SF; Mahdi WA; Alshehri S; Alnajjar R; Choi WJ; Al-Karmalawy AA; Lee K
    Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.
    Ye P; Li F; Wei Y; Zhang Y; Cui J; Dai R; Chen H; Xie J; Cai P
    Sci Rep; 2022 Jul; 12(1):12894. PubMed ID: 35902718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver.
    Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
    Acta Oncol; 2015 Apr; 54(4):480-6. PubMed ID: 25601452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases.
    Wei Q; Sheng L; Shui Y; Hu Q; Nordgren H; Carlsson J
    Ann Surg Oncol; 2008 Apr; 15(4):1193-201. PubMed ID: 18172732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome.
    Lédel F; Hallström M; Ragnhammar P; Öhrling K; Edler D
    Eur J Cancer; 2014 Feb; 50(3):656-62. PubMed ID: 24300455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.
    Yao ZX; Lu LJ; Wang RJ; Jin LB; Liu SC; Li HY; Ren GS; Wu KN; Wang DL; Kong LQ
    Med Oncol; 2014 Jan; 31(1):798. PubMed ID: 24307349
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.